No positive effect of oral magnesium supplementation in the decreases of inflammation in subjects with prediabetes: a pilot study
Simental-Mendía LE, Rodríguez-Morán M, Reyes-Romero MA, Guerrero-Romero F
Magnesium research · 23 citas
Etiquetas de revisión
Financiación no declaradaSolo mecanismosDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Solo mecanismos
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2012-07-01 · Magnes Res · vol. 25 · número 3 · págs. 140–146
- Editorial
- John Libbey Eurotext
- Citado
- 24 citas · más que el 74% de estudios similares · 0.8× el promedio de su campo
- Referencias
- 0 trabajos
- Acceso
- De pago
- Áreas de investigación
- Magnesium in Health and Disease · Magnesium Alloys: Properties and Applications · Adipokines, Inflammation, and Metabolic Diseases
- Palabras clave
- magnesium supplementation, prediabetes, inflammation, hypomagnesemia, C-reactive protein, TNF-α, interleukin-6, IL-10, magnesium chloride
- MeSH
- humans, nephrocalcinosis, renal tubular transport, inborn errors, prediabetic state, inflammation, magnesium, tumor necrosis factor-alpha, c-reactive protein, interleukin-6, interleukin-10, administration, oral, pilot projects, dietary supplements, adult, aged, middle aged, female, male, hypercalciuria, young adult
4 autores
- Luis E. Simental‐Mendía🇲🇽Mexican Social Security Institute
- Martha Rodríguez‐Morán🇲🇽Mexican Social Security Institute
- Miguel Arturo Reyes-Romero🇲🇽Mexican Social Security Institute
- Fernando Guerrero‐Romero🇲🇽Mexican Social Security Institute
Resumen
El texto original del estudio, en el idioma en que se publicó.
To determine whether oral magnesium supplementation modifies serum levels of high-sensitivity C-reactive protein (hsCRP), TNF-alpha, IL-6, and IL-10 in subjects with prediabetes, inflammation, and hypomagnesemia, a total of 26 subjects men and non-pregnant women were included and randomly allocated to receive 30 ml of MgCl(2) 5% solution (equivalent to 382 mg of magnesium) or placebo, daily during three months. At baseline conditions, there were not significant statistical differences between the groups. At end of the study, hsCRP levels were significantly lower in the intervention group (3.3 ± 2.5 vs 8.0 ± 5.9 mg/L, p = 0.03), as compared with the control group. However, the intra-group analysis of the individuals who received magnesium, did not shows significant statistical differences between baseline and final conditions (4.1 ± 3.0 and 3.3 ± 2.5, p = 0.45). In addition, TNF-alpha (1.2 ± 0.3 vs 1.1 ± 0.3 pg/mL, p = 0.69), IL-6 (0.3 ± 0.3 vs 5.0 ± 7.7 pg/mL, p = 0.08), and IL-10 (1.8 ± 0.4 vs 1.8 ± 0.5 pg/mL, p = 0.89) serum levels were not significantly different between the groups. Our results do not show a beneficial effect of oral magnesium supplementation on hsCRP, IL-6, TNF-alpha, and IL-10 levels in prediabetic subjects with hypomagnesemia and inflammation. Further studies with large sample sizes and longer time of follow-up are necessaries to verify the results of our pilot study.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.